High-velocity nasal insufflation of oxygen (HVNIO) involves use of a specialized cannula to deliver high-velocity oxygen to the nasopharynx. Theoretically, it can improve oxygenation and also improve ventilation by flushing CO2 out of the airways' dead space. Investigators conducted a multicenter, unblinded, randomized noninferiority trial to compare this method to bilevel positive airway pressure (BiPAP) in adult emergency department (ED) patients with respiratory distress. Patient eligibility criteria included no immediate need for intubation, no overdose, and clinician judgement of need for BiPAP.
A total of 204 patients were randomized to HVNIO or BiPAP. HVNIO was statistically noninferior to BiPAP for the main outcome measure, need for …
Reviewing Author
DisclosuresConsultant/Advisory BoardPortola Pharmaceuticals, Inc.
Speaker’s BureauPeerView Institute for Medical Education
Grant/Research SupportAgency for Healthcare Research and Quality; CDC; NIH–National Center for Advancing Translational Sciences; NIH–National Institute of Allergy and Infectious Diseases (NIAID); NIH–NIAID–Antibacterial Resistance Leadership Group; Merck; Pfizer; Boehringer-Ingelheim; Shire; Portola Pharmaceuticals, Inc.; Novartis; bioMérieux; Siemens; Rapid Pathogen Screening; Magnolia; Stago; Innovative Biosensors; Molecular Detection, Inc.; Dyax Corp.; Trius Pharmaceuticals
DisclosuresConsultant/Advisory BoardPortola Pharmaceuticals, Inc.
Speaker’s BureauPeerView Institute for Medical Education
Grant/Research SupportAgency for Healthcare Research and Quality; CDC; NIH–National Center for Advancing Translational Sciences; NIH–National Institute of Allergy and Infectious Diseases (NIAID); NIH–NIAID–Antibacterial Resistance Leadership Group; Merck; Pfizer; Boehringer-Ingelheim; Shire; Portola Pharmaceuticals, Inc.; Novartis; bioMérieux; Siemens; Rapid Pathogen Screening; Magnolia; Stago; Innovative Biosensors; Molecular Detection, Inc.; Dyax Corp.; Trius Pharmaceuticals